Dx
LiquidPlex™ Dx is a targeted gene panel for ctDNA that covers key biomarkers implicated in the most prevalent solid tumors, especially non-small cell lung cancer (NSCLC). CDx coverage includes METex14 splicing mutations in NSCLC in addition to pan-tumor comprehensive genomic profiling and provides highly actionable and quick therapy guidance. Coverage also includes 29 genes, including EGFR, KRAS, BRAF, ERBB2/HER2, ESR1, FGFR1, KRAS, NRAS and PIK3CA genes, plus additional key biomarkers to advance precision oncology by providing broader therapy options and optimal clinical trial enrollment. The panel is validated for use on Illumina® MiSeqDx and Illumina NextSeq 550Dx sequencers. It is powered by Anchored Multiplex PCR (AMP™) target enrichment chemistry for confident variant calling, even at low allele frequencies.
Thank You
- Key Features
- Specifications
- Gene Targets
- Additional Resources
Meets Guidelines
Content meets ESMO and country-specific guidelines
for NSCLC.
Reliable Results You Can Trust
High sensitivity and specificity even with limited sample input and low allele frequency.
Scalable and Flexible
Adaptable to flexible laboratory throughput and validated on MiseqDx and NextSeq 550Dx instruments.
Comprehensive and actionable information
Can be used in parallel with tissue profiling to provide a broader picture of tumor heterogeneity, or as a quicker testing option while tissue biopsy is being obtained or if tissue is unavailable.
Properties
Specifications
Gene Targets
29
Sample Input
cfDNA
Sample Types
Plasma
Number of Reads per Library
MiSeqDx: 4-6 M, NextSeq 550 Dx: 4-6 M
Hands-On Time
Library prep ~2.5 hrs; sequencing ~1 hr
Total Time
Results on day 4, starting with extracted nucleic acid
Platform
MiSeqDx or NextSeq 550Dx
Product Information
AKT1
ALK
AR
BRAF*
CDK6
CTNNB1
EGFR*
ERBB2*
ERBB3
ESR1
FGFR1
FGFR2
FGFR3
HRAS
IDH1
IDH2
KIT
KRAS*
MAP2K1
MET
NRAS
NTRK1
NTRK2
NTRK3
PDGFRA
PIK3CA
RET
ROS1
TP53
LEGEND
* Included in international and or local guidelines for NSCLC